Venus Remedies stock jumps over 14% to 8-week high on FDA approval for anti-mircrobial resistance therapy
Shares of Venus Remedies, one of the largest manufacturers of meropenem antibiotics and an emerging player in AMR drugs in India, popped up 14.3% in Thursday’s trading session, April 17, to reach an 8-week high of ₹356.65. This rally came after the company, in an exchange filing today, announced that its investigational product, VRP-034, has…
